STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BBIO Form 4: Director’s 10,000-share option exercise and sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) director reports option exercise and share sales. On 11/17/2025, the reporting person exercised a stock option for 10,000 shares of common stock at $16.75 per share, increasing their holdings before subsequent sales. That same day, they sold 3,801 shares of common stock at a weighted average price of $66.2481 and 6,199 shares at a weighted average price of $66.8908, all under a Rule 10b5-1 trading plan adopted on June 27, 2025. After these transactions, the reporting person directly owned 11,589 shares of BridgeBio common stock and indirectly owned 4,000 shares through Thinking Bench Capital LLC. Following the option exercise, 41,501 stock options with a $16.75 exercise price remained beneficially owned.

Positive

  • None.

Negative

  • None.
Insider Scott Randal W.
Role Director
Sold 10,000 shs ($666K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 10,000 $0.00 --
Exercise Common Stock 10,000 $16.75 $168K
Sale Common Stock 3,801 $66.2481 $252K
Sale Common Stock 6,199 $66.8908 $415K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 41,501 shares (Direct); Common Stock — 21,589 shares (Direct); Common Stock — 4,000 shares (Indirect, By Thinking Bench Capital LLC)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Represents the weighted average sale price of the shares sold from $65.64 to $66.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $66.65 to $67.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. One-third of the shares underlying the option vested on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the Reporting Person's continued service on the board of directors of the Issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scott Randal W.
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/17/2025 M(1) 10,000 A $16.75 21,589 D
Common Stock 11/17/2025 S(1) 3,801 D $66.2481(2) 17,788 D
Common Stock 11/17/2025 S(1) 6,199 D $66.8908(3) 11,589 D
Common Stock 4,000 I By Thinking Bench Capital LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $16.75 11/17/2025 M(1) 10,000 (4) 06/21/2033 Common Stock 10,000 $0 41,501 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.
2. Represents the weighted average sale price of the shares sold from $65.64 to $66.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. Represents the weighted average sale price of the shares sold from $66.65 to $67.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. One-third of the shares underlying the option vested on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the Reporting Person's continued service on the board of directors of the Issuer.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Will Solis, Attorney-in-Fact 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BridgeBio Pharma (BBIO) report on this Form 4?

The Form 4 reports that a director of BridgeBio Pharma exercised a stock option for 10,000 shares of common stock at $16.75 per share on 11/17/2025 and sold shares on the same date.

How many BridgeBio (BBIO) shares did the director sell and at what prices?

On 11/17/2025, the director sold 3,801 shares of common stock at a weighted average price of $66.2481 and 6,199 shares at a weighted average price of $66.8908.

Was the BridgeBio (BBIO) insider trading under a Rule 10b5-1 plan?

Yes. The stock sales were made under a Rule 10b5-1 sales plan that the reporting person adopted on June 27, 2025, as disclosed in the footnotes.

How many BridgeBio (BBIO) shares does the director own after these transactions?

After the reported transactions, the director directly owned 11,589 shares of common stock and indirectly owned 4,000 shares through Thinking Bench Capital LLC.

What stock options does the BridgeBio (BBIO) director still hold?

The director held 41,501 stock options with an exercise price of $16.75 per share after the 11/17/2025 exercise of 10,000 options.

How do the weighted average sale prices on this BridgeBio (BBIO) Form 4 work?

The reported prices of $66.2481 and $66.8908 are weighted average sale prices for trades executed in ranges of $65.64–$66.63 and $66.65–$67.48 per share, respectively. The reporting person has offered to provide detailed trade breakdowns upon request.

What is the vesting schedule of the BridgeBio (BBIO) stock option involved?

For the stock option exercised, one-third of the underlying shares vested on June 21, 2024, and one-third vests annually so that all shares vest by June 21, 2026, subject to continued board service.